Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: Differential effect of cigarette smoking

Cytokine

Volumn 58, Issue 3, 2012, Pages 390-397

  Chen, Ying ^a,b   Dawes, Peter T ^a   Mattey, Derek L ^a,b  

^a HAYWOOD HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Disease activity; Polymorphism; Rheumatoid arthritis; Smoking; VEGFA

Indexed keywords

BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; STEROID; VASCULOTROPIN A;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VEGFA GENE;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BASE SEQUENCE; COHORT STUDIES; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862778187     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.02.018     Document Type: Article

References (39)

1. Paleolog E.M. The vasculature in rheumatoid arthritis: cause or consequence?. Int J Exp Path 2009, 90:249-261.
2. Szekanecz Z., Koch A. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 2009, 51:1-7.
3. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
4. Ploüet J., Schilling J., Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989, 8:3801-3806.
5. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
6. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77:527-543.
7. Brogan I.J., Khan N., Isaac K., Hutchinson J.A., Pravica V., Hutchinson I.V. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999, 60:1245-1249.
8. Watson C.J., Webb N.J.A., Bottomley M.J., Brenchley P.E.C. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000, 12:1232-1235.
9. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000, 37:638-643.
10. Awata T., Inoue K., Kuihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002, 51:1635-1639.
11. Stevens A., Soden J., Brenchley P.E., Ralph S., Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003, 63:812-816.
12. Koukourakis M.I., Papazoglou D., Giatromanolaki A., Bougioukas G., Maltezos E., Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004, 46:293-298.
13. Prior S.J., Hagberg J.M., Paton C.M., Douglass L.W., Brown M.D., McLenithan J.C., et al. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 2006, 290:H1848-H1855.
14. Zhai R., Gong M.N., Zhou W., Thompson T.B., Kraft P., Su L., et al. Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 2007, 62:718-722.
15. Petrovic M.G., Korosec P., Kosnik M., Osredkar J., Hawlina M., Peterlin B., et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 2008, 14:1382-1387.
16. Steffensen K.D., Waldstrøm M., Brandslund I., Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010, 117:109-116.
17. Chen M.H., Tzeng C.H., Chen P.M., Lin J.K., Lin T.C., Chen W.S., et al. VEGF-460→C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenom J 2011, 11:227-236.
18. Lee S.S., Joo Y.S., Kim W.U., Min D.J., Min J.K., Park S.H., et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:321-324.
19. Ozgonenel L., Cetin E., Tutun S., Tonbaklar P., Aral H., Guvenen G. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2010, 29:473-477.
20. Kurosaka D., Hiral K., Nishioka M., Miyamoto Y., Yoshida K., Noda K., et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010, 37:1121-1128.
21. Klimiuk P.A., Sierakowski S., Fiedorczyk M., Chwiećko J. Serum tumor necrosis factor alpha (TNF-alpha) concentration correlations with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis. Przegl Lek 2004, 61:86-89.
22. Ballara S., Taylor P.C., Reusch P., Marmé D., Feldmann M., Maini R.N., et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
23. Han S.W., Kim G.W., Seo J.S., Kim S.J., Sa K.H., Park J.Y., et al. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology 2004, 43:1173-1177.
24. Rueda B., González-Gay M.A., López-Nevot M.A., García A., Fernández-Arquero M., Balsa A., et al. Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis. Hum Immunol 2005, 66:864-868.
25. Chen Y., Dawes P.T., Packham J.C., Mattey D.L. Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J Rheumatol 2011, 38:802-809.
26. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987, 31(1988):315-324.
27. Prevoo M.L. M.A. van't Hof, H.H. Kuper, M.A. van Leeuwen, L.B. van de Putte, P.L. van Riel, Modified disease activity scores that include twenty-eight-joints counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
28. Lin D.Y., Zeng D., Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 2005, 29:299-312.
29. Ryu S., Lee J.H., Kim S.I. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006, 25:16-20.
30. Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, et al. Linking power doppler ultrasound to the presence of TH17 cells in the rheumatoid arthritis joint, PLoS ONE 2010;5:E12516.
31. Pickens S.R., Volin M.V., Mandelin A.M., Kolls J.K., Pope R.M., Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010, 184:3233-3241.
32. Akiri G., Nahari D., Finkelstein Y., Le S.Y., Elroy-Stein O., Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998, 17:227-236.
33. Minchenko A., Salceda S., Bauer T., Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994, 40:35-39.
34. Liu Y., Cox S.R., Morita T., Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 1995, 77:638-643.
35. Manfredsdottir V.F., Vikingsdottir T., Jonsson T., Geirsson A.J., Kjartansson O., Heimisdottir M., et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:734-740.
36. Westhoff G., Rau R., Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008, 47:849-854.
37. Naranjo A., Toloza S., Guimaraes da Silveira I., Lazovskis J., Hetland M.L., Hamoud H., et al. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin Exp Rheumatol 2010, 28:820-827.
38. Söderlin M.K., Petersson I.F., Bergman S. BARFOT study group. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol 2011, 40:249-255.
39. Ruiz-Esquide V., Gómez-Puerta J.A., Cañete J.D., Graell E., Vazquez I., Ercilla M.G., et al. Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis. J Rheumatol 2011, 38:2536-2539.